You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Amicus’ Pompe disease therapy joins early access scheme

Patients with late-stage Pompe disease who are failing to respond to enzyme replacement therapy will now have early access to an alternative treatment option, after Amicus Therapeutics’¬†¬†cipaglucosidase alfa with miglustat was approved for the UK’s Early Access to Medicine Scheme (EAMS).